The Stomach Cancer That Spreads Through the Wall: Signet Ring Cell Carcinoma
Most cancers grow as a mass. Something to see, point a camera at, put a needle into. This one often does not. Signet ring cell carcinoma of the stomach spreads cell by cell inside the stomach wall, under mucosa that can look close to normal. So the endoscopy reads unremarkable. The biopsy comes back clean. Nobody missed an obvious lesion, because there was none to miss, and the forceps went where the camera pointed. The way through is not a cleverer first test. It is refusing to let one clean result close the question, the discipline Healz was built on.
This post walks it from the top: where this tumour sits in the current classification, why one endoscopic biopsy can be falsely reassuring, what the staging workup is trying to settle, the inherited form, and how it behaves once named.

What the pathologist is looking at, and why it is called a signet ring
The cell gives the thing its name. Under the microscope it carries a central, optically clear, globoid droplet of cytoplasmic mucin, with the nucleus pushed off to one side (World J Gastrointest Oncol, 2022). A round clear body with a crescent on its edge, like a ring with a stone set in it.
The WHO classification does not treat that cell as a diagnosis on its own. It files signet ring cell carcinoma inside poorly cohesive carcinoma, one of the gastric adenocarcinoma subtypes (Frontiers in Oncology, 2026); the sixth edition (2026) keeps that family and now subclassifies it into signet ring cell and non signet ring cell subtypes (Virchows Arch, 2026). Older reports describe the same behaviour as diffuse type: tumours that are poorly differentiated or undifferentiated and lack gland formation (NCI). The cells do not stick together, so they rarely build a discrete lump. They travel singly.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
Proportion decides which label you are reading. A consensus group of pathologists proposed reserving the signet ring cell label for tumours in which more than 90 percent of cells show that morphology, with two categories below it: combined poorly cohesive and signet ring cell carcinoma, where signet ring cells make up 10 to 90 percent, and poorly cohesive carcinoma not otherwise specified, where they are under 10 percent (the Verona consensus, Gastric Cancer, 2019, as reported in World J Gastrointest Oncol, 2022). So "signet ring cells present" and "signet ring cell carcinoma" are two different sentences, and the percentage separates them.
Linitis plastica is the macroscopic end of the same process: thickening and rigidity of the stomach wall, described as having the look of linen, with carcinoma cells through the full thickness and dense fibrous stroma packed around them (World J Gastrointest Oncol, 2022). The same review is explicit that the two terms are not synonyms.
Most stomach cancer workups start with Helicobacter pylori, and our guide on H. pylori and stomach cancer risk covers that route. This subtype's difficulty starts after someone has decided to look.
Why the endoscopy can look normal and the biopsy can come back clean
The reason is mechanical, not careless. In poorly cohesive gastric cancer, spread occurs mainly within the deeper tissue layers, mostly in the absence of any mucosal alteration, so conventional endoscopy and superficial biopsies may miss the diagnosis (World J Gastrointest Oncol, 2022). The forceps sample the surface. The disease is under it.
So a negative biopsy rules out what was sampled, not what is in the wall. The pattern that keeps the question open is a mismatch between the picture and the slide: a stomach that will not distend, folds that stay thick under insufflation, a radiology line about a thickened gastric wall, sitting next to histology that reads no malignancy. That combination is what prompts repeat endoscopy with deep biopsies guided by endoscopic ultrasonography, rather than a reassuring letter (World J Gastrointest Oncol, 2022). Volume of tissue matters too: a recent review of poorly cohesive gastric cancer notes that current guidelines call for at least six biopsies, partly so there is enough material for diagnosis and biomarker testing (Frontiers in Oncology, 2026); ESMO's 2026 guideline puts the figure at six to ten for advanced tumours.
What the staging workup is actually trying to settle
CT is the starting point, and in linitis plastica it can identify the areas of stomach with increased wall thickness (World J Gastrointest Oncol, 2022). Endoscopic ultrasound does double duty: it reads depth through the wall layers and guides the deep biopsies that surface sampling missed.
Then comes the question imaging cannot answer. Staging laparoscopy, with or without peritoneal washings, is recommended by ESMO for resectable gastric cancer in patients who are candidates for perioperative chemotherapy, and by NCCN from clinical stage T1b upwards, because the peritoneum has to be looked at directly (ESMO Clinical Practice Guideline, 2026; NCCN). In the PLASTIC study, staging laparoscopy found peritoneal or locally unresectable disease in 19 percent of patients, while FDG-PET/CT found distant metastases in 3 percent; between them the two tests moved 16 percent of patients from curative to palliative treatment (JAMA Surg, 2021). Peritoneal carcinomatosis has been reported in 5 to 21 percent of cases at surgical exploration in several series (World J Gastrointest Oncol, 2022).
Peritoneal washings are taken in the same sitting, and they carry a hard consequence: a positive cytology classifies the disease as stage IV (World J Gastrointest Oncol, 2022). Free cancer cells in the abdominal fluid count as distant disease even with nothing visible on the peritoneum, and the same review attributes the high failure rate of curative surgery in this subtype largely to peritoneal recurrence. Our piece on peritoneal carcinomatosis and ascites covers what that spread pattern looks like once established.
When it runs in a family: CDH1 and hereditary diffuse gastric cancer
Hereditary diffuse gastric cancer accounts for roughly 1 to 3 percent of all gastric cancers, and inactivating germline variants in CDH1 are its most common cause, with CTNNA1 variants a less frequent one (Chin Clin Oncol, 2023). CDH1 encodes E-cadherin, the protein that holds epithelial cells to each other. Lose it and you get cell detachment and disruption of tissue organisation, the same property the pathologist describes when a report says poorly cohesive.
For carriers the conversation is risk management, not symptoms. Prophylactic total gastrectomy remains the recommendation for CDH1 pathogenic variant carriers with a family history of diffuse gastric cancer, and consensus guidance discusses it as early as age 20, weighed against psychosocial factors (Chin Clin Oncol, 2023). A 2022 review of the consortium recommendations describes it in early adulthood up to around 30 (Curr Oncol, 2022). Where surgery is declined, deferred, or contraindicated, annual surveillance endoscopy is the accepted alternative.
The limits of that surveillance are the same sampling problem as above. Endoscopy remains an insensitive method for detecting occult signet ring cell carcinoma compared with what the removed stomach shows: gastrectomy specimens harbour signet ring cell foci in 80 to 100 percent of cases, including in people whose surveillance biopsies were negative, with reported false-negative rates of about 80 percent for one protocol and 38 percent for another (Chin Clin Oncol, 2023). The same review puts the lifetime risk of invasive lobular breast cancer in women with germline CDH1 variants at an estimated 42 percent.
How it behaves once it is named
Two patterns show up consistently. The first is who gets it. Signet ring cell gastric cancer is associated with a younger age at diagnosis and a more female distribution than other subtypes (World J Gastrointest Oncol, 2022). One review places onset between 55 and 61 years, about 7 years before non signet ring cell gastric cancer (Cancer Manag Res, 2019). Diffuse-type carcinomas are likewise described as occurring in younger patients with more aggressive behaviour (Frontiers in Oncology, 2026).
The second is chemotherapy response, where the evidence is mostly retrospective, so the claim should stay the size of its sources. Diffuse-type gastric cancer is typically associated with lower sensitivity to chemotherapy, and signet ring cell tumours show lower response rates than non signet ring cell tumours (Frontiers in Oncology, 2026). Series put numbers on it: a pathological complete response rate of 30.8 percent for intestinal-type against 0 percent for diffuse or mixed type, and lower clinical response (21.1 against 33.7 percent) and histopathological response (16.3 against 28.9 percent) in a neoadjuvant comparison (World J Gastrointest Oncol, 2022). Counter-evidence exists: one ex vivo study found diffuse-type and signet ring cell samples more sensitive to several drugs than intestinal-type (Cancer Manag Res, 2019). "Generally reported as less chemosensitive" is the accurate phrasing. "Chemotherapy does not work" is not.
How Healz reads two endoscopy reports months apart
Two endoscopy reports months apart, a biopsy that says no malignancy, a CT sentence about a thickened gastric wall: the meaning lives in how they sit together. Healz is equipped with memory, so it pulls the medical facts out of every upload, dates each finding, keeps abnormal values up front, and connects them across months. The clean biopsy from spring stays next to the imaging line from autumn instead of being replaced by it, and the mismatch between a rigid stomach and a negative slide stops being something a person has to remember to mention.
The rest of the case sits in the same place. One chat, not ten apps and four portals. Frontier AI works the whole picture, so the biopsy wording, the signet ring percentage and the staging note are one case rather than three errands. Healz is equipped with root-cause technology, so it does not stop at the first label: it asks the questions a rushed visit skips, cross-checks the case against more than a million rare cases, and drills past a comfortable reading of "gastritis" toward the cause. Using a cancer ai to read pathology report language you have never seen before is then the difference between a definition and an answer about your own file. You can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- What is signet ring cell gastric cancer?
A stomach cancer made of cells holding a large droplet of mucin that pushes the nucleus to one side, which is where the name comes from (World J Gastrointest Oncol, 2022). The WHO classification places it within poorly cohesive carcinoma (Frontiers in Oncology, 2026), a category the sixth edition (2026) retains and subdivides into signet ring cell and non signet ring cell subtypes. The cells do not adhere, so they infiltrate the wall singly instead of forming a lump.
- Can a stomach biopsy miss cancer?
Yes, and for this subtype that is a recognised limitation rather than an error. Spread occurs mainly in deeper tissue layers, often with no change in the mucosa above, so conventional endoscopy and superficial biopsies may miss it (World J Gastrointest Oncol, 2022). A stomach that stays thick and rigid despite negative histology is what prompts repeat endoscopy with deep biopsies guided by endoscopic ultrasound.
- What does linitis plastica mean on a report?
A stomach wall thickened and rigid, with the look of linen, because carcinoma cells have infiltrated the full thickness with dense fibrous stroma around them (World J Gastrointest Oncol, 2022). NCI describes diffuse adenocarcinomas infiltrating the gastric wall as linitis plastica. It sits close to signet ring cell carcinoma without being the same thing.
- Is signet ring cell stomach cancer hereditary?
Usually not, but there is an inherited form. Hereditary diffuse gastric cancer makes up about 1 to 3 percent of gastric cancers, and inactivating germline CDH1 variants are its most common cause (Chin Clin Oncol, 2023). For carriers with a family history of diffuse gastric cancer, prophylactic total gastrectomy remains the recommendation, discussed from as early as age 20, with annual surveillance endoscopy the accepted alternative.
- Why is signet ring cell gastric cancer harder to treat?
It is often found late, because it grows under intact mucosa and peritoneal spread is common enough that staging laparoscopy with washings is part of the workup, and a positive cytology makes the disease stage IV (World J Gastrointest Oncol, 2022). It is also generally reported as less chemosensitive than intestinal-type gastric cancer, in mainly retrospective series (Frontiers in Oncology, 2026).
A clean biopsy is a fact about a few fragments of tissue on one day, not a verdict on a stomach. The result that closed the question is rarely the one worth rereading. It is the one that sat next to it.
Written by Healz Team · Filed under Health Insights